Currently, there is no cure for psychostimulant-induced (such as cocaine and amphetamine) drug addiction. Several studies have evaluated the reversal of psychostimulant addiction using dopaminergic, serotoninergic, glutamatergic, and GABAergic strategies. Unfortunately, clinical data remain disappointing, and novel pharmacological strategies are needed. Therefore, the main goal of our research group is to investigate the epigenetic mechanisms of drug addiction and, in the longer run, to find new treatment options.
The main focus of our study is to investigate the role of epigenetic modifications (particularly DNA methylation and demethylation) in drug-dependent neuroplasticity mechanisms, to assess whether enzymes acting through epigenetic mechanisms may be pharmacotherapeutic targets in the treatment of addictive disorders, and to identify potential epigenetic drugs. Epigenetic studies are important for understanding how exposure to a drug of abuse translates to changes in gene expression and long-lasting behavioural phenotypes. Better understanding of the molecular mechanisms of drug addiction and dependence may lead to the development of novel targets for treating and preventing addictive disorders. Therefore, our research group’s more general and forward-looking aim is to investigate the role of epigenetic mechanisms in the pharmacokinetics (pharmacoepigenetics) and pharmacodynamics of psychiatric and neurological drugs.